Who
Jaime Vieser
Director
Company insider
Files Form 4 as: Director, Alaunos Therapeutics; Director, Mountain Lake Acquisition.
In numbers
- Trades disclosed
- 33
- Buys
- 3
- Sells
- 1
- Bought
- $1.0M
- Sold
- $6,022
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 4 Mar 2021
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K22,669 at $0.7444 | filing |
| 23 Jul 2026filed 27 Jul 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K8,789 at $1.92 | filing |
| 23 Jul 2026filed 27 Jul 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K8,789 at $1.92 | filing |
| 11 Jun 2026filed 15 Jun 2026 | Mountain Lake AcquisitionFunds, Shells & SPACs | SEC FORM 4 Code D | —478,010 | filing |
| 11 Jun 2026filed 15 Jun 2026 | Mountain Lake Acquisitionoption or derivative · Funds, Shells & SPACs | SEC FORM 4 Code M | —478,010 | filing |
| 11 Jun 2026filed 15 Jun 2026 | Mountain Lake Acquisitionoption or derivative | SEC FORM 4 Code M | —478,010 | filing |
| 11 Jun 2026filed 15 Jun 2026 | Mountain Lake Acquisition | SEC FORM 4 Code D | —478,010 | filing |
| 1 Jun 2026filed 4 Jun 2026 | Mountain Lake Acquisitionoption or derivative · Funds, Shells & SPACs | SEC FORM 4 Code J | —478,010 | filing |
| 1 Jun 2026filed 4 Jun 2026 | Mountain Lake Acquisitionoption or derivative | SEC FORM 4 Code J | —478,010 | filing |
| 29 Apr 2026filed 1 May 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K6,515 at $2.59 | filing |
| 29 Apr 2026filed 1 May 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K6,515 at $2.59 | filing |
| 12 Jan 2026filed 15 Jan 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K5,839 at $2.89 | filing |
| 12 Jan 2026filed 15 Jan 2026 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K5,839 at $2.89 | filing |
| 21 Nov 2025filed 26 Nov 2025 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | $17K5,340 at $3.16 | filing |
| 3 Jul 2025filed 7 Jul 2025 | TCRT Alaunos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,400 at $0.00 | filing |
| 3 Jul 2025filed 7 Jul 2025 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,400 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | TCRT Alaunos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $1,123250 at $4.49 | filing |
| 13 Apr 2025filed 15 Apr 2025 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,465 at $0.00 | filing |
| 31 Dec 2024filed 3 Jan 2025 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,3862,182 at $2.01 | filing |
| 31 Dec 2024filed 3 Jan 2025 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,636818 at $2.00 | filing |
News
Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and FundingTCRT · investorideas.com · 13 Oct 2026Alaunos Therapeutics Announces Acquisition of Velaris TherapeuticsTCRT · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Jaime Vieser; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.